Arbutus Biopharma Corp expected to post a loss of 2 cents a share - Earnings Preview

Arbutus Biopharma

31/07/2026 14:14

Arbutus Biopharma Corp ABUS.OQ ABUS.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026
The Warminster Pennsylvania-based  company is expected to report a 93.5% decrease in revenue to $700 thousand from $10.74 million a year ago, according to the estimate from one analyst, based on LSEG data.
​LSEG's mean analyst estimate for Arbutus Biopharma Corp is for a loss of 2 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.50, about 24.7% above its last closing price of $4.41
This summary was machine generated July 31 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)